Abstract

The present disclosure provides compositions and methods for reducing inflammation to improve or maintain mental health or physical health in an individual. In some aspects, the compositions include at least one 5HT2A agonist and at least one TRP agonist, wherein the therapeutically effective amount of the 5HT2A agonist is between about 1 μg and about 300 mg and the therapeutically effective amount of the at least one TRP receptor agonist is between about 0.01 mg and about 300 mg. The compositions may be formulated for any suitable ingestion mode, including gastrointestinal, transmucosal and parenteral.

IPC Classes  ?

• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 36/06 - Fungi, e.g. yeasts
• A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/11 - Aldehydes
• A61K 31/12 - Ketones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present disclosure provides compositions and methods for reducing inflammation to improve or maintain mental health or physical health in an individual. In some aspects, the compositions include at least one 5HT2A agonist and at least one TRP agonist, wherein the therapeutically effective amount of the 5HT2A agonist is between about 1 μg and about 300 mg and the therapeutically effective amount of the at least one TRP receptor agonist is between about 0.01 mg and about 300 mg. The compositions may be formulated for any suitable ingestion mode, including gastrointestinal, transmucosal and parenteral.

IPC Classes  ?

• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
• A61K 31/12 - Ketones
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
• A61K 36/06 - Fungi, e.g. yeasts
• A61K 36/185 - Magnoliopsida (dicotyledons)
• C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
• C07C 233/20 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
• C07C 43/285 - Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings having unsaturation outside the six-membered aromatic rings
• C07C 43/295 - Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
• C07D 209/16 - Tryptamines
• C07D 209/20 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
• C07F 9/572 - Five-membered rings